|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online 7 March 2006
doi: 10.1242/jcs.02883
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research Article |
B ligand and inhibits osteoclastogenesis in vitro
1 Biomedical Tissue Research, Department of Biology, University of York, PO Box 373, York, YO10 5YW, UK
2 Department of Anatomy and Developmental Biology, University College London, Gower Street, London, WC1E 6BT, UK
* Author for correspondence (e-mail: gjs6{at}york.ac.uk)
Accepted 22 November 2005
Reports implicating Wnt signalling in the regulation of bone mass have prompted widespread interest in the use of Wnt mimetics for the treatment of skeletal disorders. To date much of this work has focused on their anabolic effects acting on cells of the osteoblast lineage. In this study we provide evidence that Wnts also regulate osteoclast formation and bone resorption, through a mechanism involving transcriptional repression of the gene encoding the osteoclastogenic cytokine receptor activator of NF
B ligand (RANKL or TNFSF11) expressed by osteoblasts. In co-cultures of mouse mononuclear spleen cells and osteoblasts, inhibition of GSK3ß with LiCl or exposure to Wnt3a inhibited the formation of tartrate-resistant acid phosphatase-positive multinucleated cells compared with controls. However, these treatments had no consistent effect on the differentiation, survival or activity of osteoclasts generated in the absence of supporting stromal cells. Activation of Wnt signalling downregulated RANKL mRNA and protein expression, and overexpression of fulllength ß-catenin, but not transcriptionally inactive ß-catenin 
C(695-781), inhibited RANKL promoter activity. Since previous studies have demonstrated an absence of resorptive phenotype in mice lacking LRP5, we determined expression of a second Wnt co-receptor LRP6 in human osteoblasts, CD14+ osteoclast progenitors and mature osteoclasts. LRP5 expression was undetectable in CD14-enriched cells and mature human osteoclasts, although LRP6 was expressed at high levels by these cells. Our evidence of Wnt-dependent regulation of osteoclastogenesis adds to the growing complexity of Wnt signalling mechanisms that are now known to influence skeletal function and highlights the requirement to develop novel therapeutics that differentially target anabolic and catabolic Wnt effects in bone.
Key words: ß-catenin, Osteoblast, Osteoclast, Receptor activator of NFB ligand, T-cell factor, Wnt
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Ueland, K. Otterdal, T. Lekva, B. Halvorsen, A. Gabrielsen, W. J. Sandberg, G. Paulsson-Berne, T. M. Pedersen, L. Folkersen, L. Gullestad, et al. Dickkopf-1 Enhances Inflammatory Interaction Between Platelets and Endothelial Cells and Shows Increased Expression in Atherosclerosis Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1228 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Qiang, B. Hu, Y. Chen, Y. Zhong, B. Shi, B. Barlogie, and J. D. Shaughnessy Jr Bortezomib induces osteoblast differentiation via Wnt-independent activation of {beta}-catenin/TCF signaling Blood, April 30, 2009; 113(18): 4319 - 4330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Sato, A. Nakashima, M. Nashimoto, Y. Yawaka, and M. Tamura Bone morphogenetic protein-2 enhances Wnt/beta-catenin signaling-induced osteoprotegerin expression. Genes Cells, February 1, 2009; 14(2): 141 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Pinzone, B. M. Hall, N. K. Thudi, M. Vonau, Y.-W. Qiang, T. J. Rosol, and J. D. Shaughnessy Jr The role of Dickkopf-1 in bone development, homeostasis, and disease Blood, January 15, 2009; 113(3): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nie and E. H. Sage SPARC Inhibits Adipogenesis by Its Enhancement of {beta}-Catenin Signaling J. Biol. Chem., January 9, 2009; 284(2): 1279 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Modarresi, Z. Xiang, M. Yin, and J. Laurence WNT/{beta}-Catenin Signaling Is Involved in Regulation of Osteoclast Differentiation by Human Immunodeficiency Virus Protease Inhibitor Ritonavir: Relationship to Human Immunodeficiency Virus-Linked Bone Mineral Loss Am. J. Pathol., January 1, 2009; 174(1): 123 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aicher, O. Kollet, C. Heeschen, S. Liebner, C. Urbich, C. Ihling, A. Orlandi, T. Lapidot, A. M. Zeiher, and S. Dimmeler The Wnt Antagonist Dickkopf-1 Mobilizes Vasculogenic Progenitor Cells via Activation of the Bone Marrow Endosteal Stem Cell Niche Circ. Res., October 10, 2008; 103(8): 796 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Hoverter and M. L. Waterman A Wnt-fall for Gene Regulation: Repression Sci. Signal., September 30, 2008; 1(39): pe43 - pe43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth Blood, July 15, 2008; 112(2): 374 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-W. Qiang, Y. Chen, O. Stephens, N. Brown, B. Chen, J. Epstein, B. Barlogie, and J. D. Shaughnessy Jr Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma Blood, July 1, 2008; 112(1): 196 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Edwards, J. R. Edwards, S. T. Lwin, J. Esparza, B. O. Oyajobi, B. McCluskey, S. Munoz, B. Grubbs, and G. R. Mundy Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo Blood, March 1, 2008; 111(5): 2833 - 2842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Delmas, F. Beermann, S. Martinozzi, S. Carreira, J. Ackermann, M. Kumasaka, L. Denat, J. Goodall, F. Luciani, A. Viros, et al. beta-Catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development Genes & Dev., November 15, 2007; 21(22): 2923 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.H. Li and S. Amar Inhibition of SFRP1 Reduces Severity of Periodontitis Journal of Dental Research, September 1, 2007; 86(9): 873 - 877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Shaughnessy Jr. Going Against the Grain: Promoting Wnt Signaling to Conquer Cancer Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 19 - 24. [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Bodine Wnt Signaling in Bone IBMS BoneKEy, March 1, 2007; 4(3): 108 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie, and J. D. Shaughnessy Jr Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood, March 1, 2007; 109(5): 2106 - 2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Clines, K. S. Mohammad, Y. Bao, O. W. Stephens, L. J. Suva, J. D. Shaughnessy Jr., J. W. Fox, J. M. Chirgwin, and T. A. Guise Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation Mol. Endocrinol., February 1, 2007; 21(2): 486 - 498. [Abstract] [Full Text] [PDF]
|
|
